Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the <scp>EMPA‐REG OUTCOME</scp> trial with a focus on Asia
Qiuhe Ji(Medical Center Hospital), Odd Erik Johansen(Boehringer Ingelheim (Norway)), Linong Ji(Peking University), Christoph Wanner(Universitätsklinikum Würzburg), Jyothis T. George(Boehringer Ingelheim (China)), Wataru Ogawa(Kobe University), Isabella Zwiener(Boehringer Ingelheim (Germany)), Koutaro Yokote(Chiba University), Kohjiro Ueki(Institute for Security Studies), Jiajun Zhao(Shandong Provincial Hospital), Bernard Zinman(Mount Sinai Hospital), Yiming Mu(Chinese PLA General Hospital)
Cited by 25
Related Papers
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
|New England Journal of Medicine|2015|11.9k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase
|Nature Medicine|2002|4.2k
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k